Jonas Wixner
Overview
Explore the profile of Jonas Wixner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
376
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Adams D, Wixner J, Polydefkis M, Berk J, Conceicao I, Dispenzieri A, et al.
JAMA Neurol
. 2025 Jan;
82(3):228-236.
PMID: 39804640
Importance: There is a lack of long-term efficacy and safety data on hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) and on RNA interference (RNAi) therapeutics in general. This study presents the...
2.
Wixner J, Berk J, Adams D, Polydefkis M, Conceicao I, Attarian S, et al.
Amyloid
. 2024 Nov;
32(1):29-38.
PMID: 39552152
Background: The NEURO-TTRansform trial showed that after 66 weeks of treatment, eplontersen significantly reduced neuropathic impairment and improved quality of life (QoL) in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy...
3.
Folkvaljon F, Gertz M, Gillmore J, Khella S, Masri A, Maurer M, et al.
Muscle Nerve
. 2024 Nov;
71(1):96-107.
PMID: 39552102
Introduction/aims: The degree of change in neuropathic impairment and quality of life (QoL) that is clinically meaningful to patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) is not established. This...
4.
Senem I, Foss M, Lavigne-Moreira C, Dos Santos A, de Franca Nunes R, Franca Junior M, et al.
Neurol Sci
. 2024 Nov;
46(3):1349-1358.
PMID: 39499456
Background: Central nervous system symptoms, such as cognitive dysfunction, have been reported in Hereditary Transthyretin Amyloidosis (ATTRv). However, there is a lack of neuroimaging studies investigating structural alterations in the...
5.
Pilebro B, Wixner J, Anan I
Amyloid
. 2024 Aug;
31(4):342-343.
PMID: 39126640
No abstract available.
6.
Gonzalez-Moreno J, Dispenzieri A, Grogan M, Coelho T, Tournev I, Waddington-Cruz M, et al.
Cardiol Ther
. 2023 Dec;
13(1):117-135.
PMID: 38117424
Introduction: Transthyretin amyloidosis (ATTR amyloidosis) is primarily associated with a cardiac or neurologic phenotype, but a mixed phenotype is increasingly described. Methods: This study describes the mixed phenotype cohort in...
7.
Gentile L, Coelho T, Dispenzieri A, Conceicao I, Waddington-Cruz M, Kristen A, et al.
Orphanet J Rare Dis
. 2023 Nov;
18(1):350.
PMID: 37946256
Background: Transthyretin amyloidosis (ATTR amyloidosis) is a progressive, multisystemic, life-threatening disease resulting from the deposition of variant or wild-type (ATTRwt amyloidosis) transthyretin amyloid fibrils in various tissues and organs. Methods:...
8.
Coelho T, Marques Jr W, Dasgupta N, Chao C, Parman Y, Franca Jr M, et al.
JAMA
. 2023 Sep;
330(15):1448-1458.
PMID: 37768671
Importance: Transthyretin gene silencing is an emerging treatment strategy for hereditary transthyretin (ATTRv) amyloidosis. Objective: To evaluate eplontersen, an investigational ligand-conjugated antisense oligonucleotide, in ATTRv polyneuropathy. Design, Setting, And Participants:...
9.
Thorn R, Hemmingsson O, Borssen A, Werner M, Karling P, Wixner J
J Hepatocell Carcinoma
. 2023 Sep;
10:1573-1586.
PMID: 37753268
Purpose: Surveillance for hepatocellular carcinoma (HCC) is recommended in at-risk patients, but its effectiveness in Western populations has been questioned. The purpose was to evaluate the effect of surveillance in...
10.
Coelho T, Dispenzieri A, Grogan M, Conceicao I, Waddington-Cruz M, Kristen A, et al.
Amyloid
. 2023 Jul;
30(4):445-448.
PMID: 37459334
No abstract available.